期刊文献+

卢雯平基于孙桂芝学术思想治疗乳腺癌思路探讨 被引量:6

Discussion on LU Wenping’s treatment thoughts of breast cancer based on SUN Guizhi’s academic ideology
暂未订购
导出
摘要 孙桂芝教授从医60余年,在乳腺癌的中西医诊疗方面积累了丰富的临床经验。卢雯平教授在20多年的临床诊疗过程中,基于孙桂芝教授中西医结合治疗乳腺癌的核心思想,发展提出三辨论治思想,根据不同治疗阶段的病机特点,结合全方位、全周期综合管理治疗模式治疗乳腺癌,临床疗效颇佳。 Professor SUN Guizhi has been a doctor for more than 60 years and hasaccumulated rich clinical experience in the diagnosis and treatment of breast cancer in traditional Chinese and Western medicine.Over the 20 years’clinical practice,Professor LU Wenping proposed a treatment with three differentiation based on Professor SUN Guizhi’s core idea of treating breast cancer with intergrated traditional Chinese and Western medicine.The treatment is combined with comprehensive treatment model of all-round and full-cycle according to the pathogenesis features of different treatment phases,and the curative effect is good.
作者 陈秋叶 卢雯平 CHEN Qiuye;LU Wenping(Beijing University of Chinese Medicine,Beijing 100029,China;Department of Oncology,Guang’anmen Hospital of China Academy of Chinese Medical Sciences,Beijing 100053,China)
出处 《天津中医药大学学报》 CAS 2021年第1期27-30,共4页 Journal of Tianjin University of Traditional Chinese Medicine
关键词 乳腺癌 病因病机 三辨论治 中西汇通 breast cancer etiology and pathogenesis treatment based on three differentiation the confluence of Chinese and Western
  • 相关文献

参考文献7

二级参考文献120

  • 1张思维,雷正龙,李光琳,邹小农,陈万青,赵平.中国肿瘤登记地区2005年发病死亡资料分析[J].中国肿瘤,2009,18(12):973-979. 被引量:33
  • 2王启俊,祝伟星,邢秀梅.北京城区女性乳腺癌发病死亡和生存情况20年监测分析[J].中华肿瘤杂志,2006,28(3):208-210. 被引量:80
  • 3薛飞飞,陈家旭.对“微观辨证”的思考与展望[J].中医杂志,2007,48(2):104-106. 被引量:37
  • 4王琦,王睿林,李英帅.中医体质学学科发展述评[J].中华中医药杂志,2007,22(9):627-630. 被引量:125
  • 5Miller KD, Wang M, Gralow J, et al. Paclitaxel plus bevacizum- ab versus paclitaxel alone for metastatic breast cancer[ J]. N En- gl J Med, 2007, 357(26) :2666 -2676.
  • 6Miles DW, Chan A, Romieu G, et al. Randomized, double- blind, placebo-controlled, phase m study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for pa- tients with locally recurrent or metastatic breast cancer (mBC) : AVADO[ J]. J Clin Oncol, 2008,26( 15 Suppl) : al011.
  • 7Robert N J, Dieras V, Glaspy J, et al. RIBBON-1 : Randomized, double-blind, placebo-controlled, phase III trial of chemotherapywith or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) [ J]. J Clin Oncol,2009,27( 15 Suppl) : a1005.
  • 8Cohn AL, Bekaii-Saab T, Bendell JC, et al. Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV be- yond progression (BBP)[J]. J Clin Oncol, 2010,28( 15 Sup- pl) : a3596.
  • 9Tabernero J, Aranda E, Gomez A, et al. Phase 111 study of first- line XELOX plus bevacizumab (BEV)for 6 cycles followed by XELOX plus BEV or single-agent ( s,/a ) BEV as maintenance therapy in patients (pots)with metastatic colorectal cancer (mCRC) :The MACRO Trial( Spanish Cooperative Group for the Treatment of Digestive Tumors[ TYD] ) [ J]. J Clin Oncol, 2010, 28(15 Suppl) : a3501.
  • 10Lueio C, Eric D, Pilar G, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small- cell lung cancer (SAIL, MO19390) : a phase 4 study[Jl. Lan- cet Oneol, 2010,11 (8) :733 - 740.

共引文献470

同被引文献59

引证文献6

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部